Steps 5 and 6 of the process for RBQM in clinical trials described in Section 5.0 of ICH E6(R2) are to communicate quality management activities and review risk control measures periodically. What are the leading practices in this area? Who should you communicate risk controls to? And how? When should risk reviews take place? Should all risks be reviewed or only the high-priority ones? Join us at this live workshop as our two experts provide their perspectives on these questions and, if you’d like, take the opportunity to ask your questions, brainstorm examples, and join the discussion.